CHF 0.00
In stock
SYN-1076-M0011 mgCHF 270.00
SYN-1076-M0055 mgCHF 546.00
SYN-1076-M01010 mgCHF 858.00
SYN-1076-M05050 mgINQ
SYN-1076-M100100 mgINQ
More Information
Product Details
Synonyms SB-242235
Product Type Chemical
Formula C19H20FN5O
MW 353.4
CAS 193746-75-7
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: p38 | Kinase Group: CMGC | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
The p38 mitogen-activated protein kinase (MAPK) signaling pathway is activated by numerous inflammatory mediators and environmental stresses. SB-242235 is a potent and moderately selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases such as autoimmune or inflammatory diseases. SB-242235 exhibits good oral availability in preclinical studies and has micromolar or submicomolar in vivo IC(50) values. However it is clear from studies examining SB-242235 effects on metabolism, for instance in chondrocytes and human cartilage that SB-242235 effects can be pleiotropic between species and that care must be taken when studying the interactions of multi-target inhibitors such as SB-242235.
Product References
  1. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis: A.M. Badger, et al.; Arthritis Rheum. 43, 175 (2000)
  2. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity: J.L. Adams, et al.; Bioorg. Med. Chem. Lett. 11, 2867 (2001)
  3. SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics: K.W. Ward, et al.; Xenobiotica 32, 221 (2002)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.